Immunology Company Kira Biotech launches with A$20M Series A Funding
Related Articles
-
Arrow / HCC PhD scholarship recipient is closer to discovering a new treatment option
Featured in the Arrow Newsletter, Issue 2, 2015. Michael Papadimitrious, from Dendritic Cell Research, prepares his first paper. Michael is...
-
Global leader predicted for medical research
Featured in Burwood Scene, June 18, 2014. TREASURER Joe Hockey has declared that Australia will become a global leader...
-
DCR Honours Student has fallen in love with hard work
Kate Chen, promising honours student in the DCR team, wins Concord Hospital Early Career Research Competition. Kate Chen came...
-
An answer to cancer
Featured in Burwood Scene, July 3, 2013. Acute Myeloid Leukaemia is a blood cancer. We know it as bone marrow...
-
Editor’s Desk: The Appeal Starts Here
Featured in Burwood Scene, July 3, 2013. I met Professor Derek Hart at Concord hospital eight months ago when...
-
Anti-cancer vaccine within reach
Featured in Burwood Scene, August 28, 2012. EXCLUSIVE: A 20-strong team of medical researchers led by Professor Derek Hart...
-
John’s Multiple Myeloma Story
Featured in MyeNews, Spring Issue, 2015. John Fullagar gave the consumers perspective at the recent DC Down Under Symposium DC...
-
Dreadlocks anyone?
Cristian Silveira donates money raised to Dendritic Cell Research Cristian Silveira had been growing his hair for about 17...
![](mailto:?subject=Immunology Company Kira Biotech launches with A$20M Series A Funding&body=
<img class="aligncenter wp-image-3224 size-medium" src="http://dcresearch.org.au/wp-content/uploads/2019/10/Kira-Biotech-logo-300x150.jpg" alt="" width="300" height="150" /><br />
Brisbane, 29 October 2019: Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders.
The round was led by OneVentures, with significant investment from IP Group and support from the Advance Queensland Business Development Fund. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies. <a style="color: #ffcc00;" href="https://kirabiotech.com/wp-content/uploads/2019/10/20191024-Kira-Biotech-Series-A-funding-press-release.pdf">Read More</a>
http://dcresearch.org.au/immunology-company-kira-biotech-launches-with-a20m-series-a-funding/){kind=link}